Skip to content
  1. Home
  2. resources
  3. poster viral sars cov 2 rebound rates in linked commercial pharmacy based sars cov 2 rt qpcr testing and healthcare claims

Poster: Viral SARS-CoV-2 rebound rates in linked commercial pharmacy-based SARS-CoV-2 RT-qPCR testing and healthcare claims

Download Poster PDF

Background

Viral SARS-CoV-2 rebound has not been well characterized across subpopulations or in large cohorts outside of clinical trials. Uncertainty around rebound has led to the potential under-utilization of nirmatrelvir/ritonavir (NMV-r) treatment.

Key question: What is the rate of viral SARS-CoV-2 rebound in patients treated with NMV-r compared to patients who are not treated?

Share

Categories